Stay updated with breaking news from Repligen Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Repligen Co. (NASDAQ:RGEN – Get Rating) – Research analysts at SVB Leerink lowered their Q4 2023 earnings per share estimates for Repligen in a note issued to investors on Tuesday, May 2nd. SVB Leerink analyst P. Souda now forecasts that the biotechnology company will post earnings per share of $0.63 for the quarter, down from […]
Gulf International Bank UK Ltd bought a new stake in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 10,515 shares of the biotechnology company’s stock, valued at approximately $1,780,000. A number of other hedge funds and other institutional […]
Mitsubishi UFJ Kokusai Asset Management Co. Ltd. bought a new stake in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 16,431 shares of the biotechnology company’s stock, valued at approximately $2,662,000. Other large investors also recently added […]
Repligen (NASDAQ:RGEN – Get Rating) had its price objective reduced by Deutsche Bank Aktiengesellschaft from $180.00 to $165.00 in a research report sent to investors on Wednesday, The Fly reports. Other equities research analysts have also recently issued reports about the stock. Benchmark reduced their price target on shares of Repligen from $230.00 to $210.00 […]
Repligen (NASDAQ:RGEN – Get Rating) had its price target lowered by research analysts at Deutsche Bank Aktiengesellschaft from $180.00 to $165.00 in a report issued on Wednesday, The Fly reports. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential upside of 4.94% from the company’s current price. RGEN has been the subject of several other reports. […]